The leukocyte migration inhibition (LMI) technique was used to measure the T cell-mediated immune response of Epstein-Barr-virus (EBV)-seropositive human donors to antigens associated with B cell lines of simian origin, transformed by simian EBV-like viruses, Herpesvirus papio (HVP), H. pan, H. gorilla and H. pongo. Extracts of cell lines carrying three of the four simian viruses (from gorilla, chimpanzee and orangutan) induced a positive LMI response, whereas lines carrying baboon-derived HVP were ineffective. None of the simian virus-transformed lines elicited an LMI reaction in human EBV-seronegative individuals. Leukocytes from patients with acute infectious mononucleosis (IM) failed to respond to any of the lines transformed by EBV or the simian EBV-like viruses. Such lines express the virally encoded nuclear antigen, but have only a low level of viral cycle-associated antigens. Extracts of the EBV-carrying human cell line P3HR-1 induced with 12-O-tetradecanoylphorbol-13-acetate to express high levels of early and virus capsid antigens (EA, VCA, respectively) however, elicited a strong response with leukocytes from patients with acute IM. During convalescence, IM patients became responsive to EBV, H. gorilla-, H. pan- and H. pongo-transformed lines, indicating that the LMI reaction induced by these simian virus-transformed lines was directed against the antigens expressed in immortalized cells rather than against antigens of the lytic cycle. It is highly probable that this reaction reflects a cross-recognition of the nuclear antigens associated with these four transforming viruses (excluding H. papio) at the level of human T cells.

Keywords:
EBV, SimianEBV-likeviruses, Herpesvirus, H.papio, H.pan, H.pongo, H. gorilla, Leukocyte migration inhibition, Cross-reaction
This content is only available via PDF.
© 1986 S. Karger AG, Basel
1986
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.